REG - Science in Sport PLC - Issue of Equity and Total Voting Rights

Science in SportAnnouncement

29/12/2023 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231229:nRSc2286Ya&default-theme=true

RNS Number : 2286Y  Science in Sport PLC  29 December 2023

 

Science in Sport plc

(the "Company")

Issue of Equity

and

Total Voting Rights

 

Science in Sport plc (AIM: SIS), the premium performance nutrition company
serving elite athletes, sports enthusiasts, and the active lifestyle
community, announces that a total of 9,852,866 ordinary shares of 10p each in
the Company ("Ordinary Shares") have been issued and allotted in relation to
the exercise of options in respect of the Company's LTIP scheme.

Application has been made to the London Stock Exchange for the admission of
9,852,866 new Ordinary Shares to trading on AIM. Admission is expected to take
place at 8.00 am on 4 January 2024 and dealings in the shares will commence at
that time.

 The Company's total issued share capital immediately following admission
will consist of 182,272,607 Ordinary Shares with one voting right per share.
The above figure of 182,272,607 Ordinary Shares may be used by shareholders as
the denominator for the calculations by which they can determine if they are
required to notify their interest in, or a change to their interest in, the
Company following admission.

 

For further information:

 Science in Sport plc                     T: 020 7400 3700
 Dan Wright, Executive Chairman

 Daniel Lampard, CFO

 Liberum (Nominated Adviser and Broker)   T: 020 3100 2000
 Richard Lindley

 John More

 

 Notes to Editors

About Science in Sport plc

Headquartered in London, Science in Sport plc is a leading sports nutrition
business that develops, manufactures, and markets innovative nutrition
products for professional athletes, sports and fitness enthusiasts and the
active lifestyle community. The Company has two highly regarded brands, PhD
Nutrition, a premium active-nutrition brand targeting the active lifestyle
community, and SiS, a leading endurance nutrition brand among elite athletes
and professional sports teams.

 

The two brands sell through the Company's phd.com and scienceinsport.com
digital platforms, third-party online sites, including Amazon and Tmall, and
extensive retail distribution in the UK and internationally, including major
supermarkets, high street chains and specialist sports retailers. This
omnichannel footprint enables the Company to address the full breadth of the
sports nutrition market, sports nutrition market, worth $24.6bn in 2022 and
forecast to grow CAGR 5.9% from 2022 to 2027.(1)

( )

SiS, a leading endurance nutrition business founded in 1992, has a core range
comprising gels, powders and bars

focused on energy, hydration, and recovery. SiS is an official endurance
nutrition supplier to over 320 professional teams, organisations, and national
teams worldwide.

 

SiS is Performance Solutions partner to Ineos Grenadiers cycling team,
Tottenham Hotspur and CGC Nice football, as well as Official Nutrition Partner
to the Milwaukee Bucks, 2021 National Basketball Association Champions.

 

PhD is one of the UK's leading active nutrition brands with a reputation for
high quality and product innovation. The brand has grown rapidly since its
launch in 2005. The range now comprises powders, bars, and supplements,
including the high protein, low sugar range, PhD Smart. PhD brand ambassadors
include leading endurance and strength athlete Ross Edgley and influencer
Gabby Allen.

 

For further information, please visit phd.com and scienceinsport.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEAFANAFPDFFA